In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Progyny’s current price at $31.40 is below its PERT-weighted fair value of $70.47, suggesting potential undervaluation with high confidence across five methods, notably robust P/E and EV/EBITDA valuations. Monte Carlo analysis reveals substantial downside risk (83.3%) and high volatility (57.25% coefficient of variation), reflecting significant uncertainty despite strong liquidity and leverage scores. Growth scores are weak (2/5), indicating potential challenges scaling profitability and efficiency.